Top 10 Global Pharmaceutical Company Awards $2.3 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring and Inf

Top 10 Global Pharmaceutical Company Awards $2.3 Million in
Studies to eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services
Phase III Program Award Consistent with Recent ICH, E14 Implementation Guidance
and Reinforces Importance of Cardiac Safety Monitoring in Later Phase Clinical
Development 


PHILADELPHIA, June 13  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic
(ECG) collection and interpretation services, announced today that it has been
awarded more than $2.3 million in cardiac safety monitoring and services from a
top 10 global pharmaceutical organization for one of its key drug candidates in
late phase clinical trials.

The award for the Phase III program is comprised of a number of studies with an
investigator network that spans three continents.  eRT will provide
comprehensive support, including provision of 270 units of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data that is
subsequently provided to eRT for analysis.  eRT will perform digital
collection, measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT(R) workflow enabled data handling technology,
the first solution in production that was designed explicitly to meet emerging
international regulatory guidance and technical standards.

"We are pleased that the ICH committee ratified implementation (step 4) of the
E14 cardiac safety monitoring guidance that reinforces cardiac safety
monitoring in all phases of clinical development. This contract represents an
example of large pharmaceutical company adopting the principles in the most
recent guidance document," said Scott Grisanti, senior vice president of
business development and chief marketing officer at eRT.  "In addition to
experience with this compound, eRT's equipment marshalling and logistics
capabilities, along with extensive site support and comprehensive project
management, were important factors in the sponsor's decision process."

Based in Philadelphia, PA, eResearchTechnology, Inc. ( http://www.ert.com/ ) is
a provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. The sponsor may cancel this agreement at its sole discretion.  As a
result, actual results may differ materially from any financial outlooks stated
herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT: Joan Sterlacci of eResearchTechnology, Inc., [phone]; or

Matt Hayden of Hayden Communications, [phone]



Web site: http://www.ert.com/ 

Copyright